Fierce Pharma

MAY 9, 2024

Five months out from their twin FDA approvals in sickle cell disease (SCD), who’s winning the race to treat patients with their respective gene therapies—bluebird bio or partners Vertex Pharmaceuti | Five months out from their twin FDA approvals in sickle cell disease (SCD), who’s winning the race to treat patients with their respective gene therapies—bluebird bio or partners Vertex Pharmaceuticals and CRISPR Therapeutics?

Leads 227

Leads Patients FDA Pharmaceutical 227

MedCity News

MAY 9, 2024

A Q&A with Naoki Okamura revealed that when it comes to cell and gene therapies, the CEO of Astellas Pharma believes risk-taking is a must for eventual success. The post Astellas CEO Q&A (Part 1): There Is No Playbook on Cell and Gene Therapies appeared first on MedCity News.

Pharma 106

Pharma Biopharma 106

Fierce Pharma

MAY 9, 2024

While Merck & Co.’s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therap | While Merck & Co.’s Keytruda already boasts a pair of approvals to treat certain forms of endometrial cancer, a recent effort to prove the PD-1 inhibitor’s worth as a post-surgery add-on therapy in newly diagnosed patients has fallen short.

Patients 222

Patients 222

MedCity News

MAY 9, 2024

On Wednesday, Ascension noticed that a hacker had infiltrated its systems. As the health system works with Mandiant to investigate the incident, clinical services remain disrupted at Ascension facilities across several states. The post Ascension Hospitals Across Several States Are Offline Following Cyberattack appeared first on MedCity News.

104

104

Advertisement

Fierce Pharma

MAY 9, 2024

After telegraphing more than a hundred potential layoffs in March in connection with plans to stop construction of a massive Seagen facility, Pfizer is plowing ahead with efforts to streamline its | Pfizer has proposed another round of staff reductions and role changes at legacy Seagen, this time hitting Seagen’s European headquarters in Switzerland, where 74 positions could be up for the chop.

221

221

Pharmaceutical Commerce

MAY 9, 2024

In an interview with Pharma Commerce Editor Nicholas Saraceno, Cathy O'Brien, VP of Sales, UPS Healthcare discusses her masterclass on delivering agility in supply chains by building a multimodal cold chain network while also reducing risks at LogiPharma Europe 2024.

Networking 100

Networking Pharma Sales Healthcare 100

ALULA

MAY 9, 2024

In the US alone, 6.2 percent of the total population identify as AANHPI (Asian American, Native Hawaiian, Pacific Islander). May is dedicated to honoring people in the US with AANHPI heritage , so it’s a great time to celebrate their voices and experiences – and to reflect on how we can integrate their stories into our lives all year long , especially with our colleagues and teams.

98

98

Fierce Pharma

MAY 9, 2024

In response to rapidly declining profits and the downfall of ADHD drug Vyvanse, Takeda is planning to throw 140 billion Japanese yen ($899 million) toward a company-wide restructuring campaign. | In a multi-year overhaul, the Japanese drugmaker plans to prioritize "organizational agility," procurement savings and tech efficiencies. It's all part of an effort to boost profit margins.

161

161

ALULA

MAY 9, 2024

Welcome back to our series, begun here , on what today’s leaders and workers can learn from AA and NHPI people whose work demonstrates a profound commitment to behaviors with a lasting positive impact.

98

98

Fierce Pharma

MAY 9, 2024

In the dynamic world of life sciences, digital pathology stands out as a beacon of innovation, promising transformative changes in how pathologists engage, evaluate, and collaborate. | Sitting down with Agilent Technologies, we explore the challenges and opportunities of incorporating digital pathology solutions within companion diagnostics.

130

130

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

ALULA

MAY 9, 2024

We enjoyed exploring the story of Shuji Nakamura here , and we’re grateful to you for reading our series on what today’s leaders and workers can learn from AA and NHPI people whose work demonstrates a profound commitment to behaviors with a lasting positive impact.

97

97

Fierce Pharma

MAY 9, 2024

Takeda has entered into a restructuring to achieve “organizational simplicity.” Innovent Biologics' GLP-1R/GCGR dual agonist, licensed from Eli Lilly, has notched a second positive phase 3 rea | Takeda launched a restructuring to achieve “organizational simplicity.” Innovent and Eli Lilly's GLP-1R/GCGR dual agonist notched a second positive phase 3 readout.

Biopharma 130

Biopharma Pharma Patients 130

MedCity News

MAY 9, 2024

One irony of personalized or precision medicine (PM) is that it aims, against the advice of Hippocrates and Osler, to treat the disease, not the patient. The post Why Personalized Medicine Should Not Be Too Personalized appeared first on MedCity News.

Medicine 94

Medicine Patients Biopharma 94

Fierce Pharma

MAY 9, 2024

US gene therapy approvals create a big problem for Brazil.

FDA 180

FDA 180

Advertisement

Distribution

pharmaphorum

MAY 9, 2024

A UK report has said that inflation and geopolitical instability have led to a “dramatic drop” in investment in smaller companies developing new medicines, with a knock-on effect on the entire life sciences industry.

Medicine 94

Medicine 94

MedCity News

MAY 9, 2024

Many consumers leave their provider because of navigation problems, while many leave their insurer because of experience issues, a new Accenture report found. The post Why Consumers Leave Their Payer/Provider appeared first on MedCity News.

Insurance 90

Insurance Patients 90

European Pharmaceutical Review

MAY 9, 2024

Withdrawal of the marketing authorisation for the COVID-19 vaccine (ChAdOx1-S [recombinant]) Vaxzevria (SRD) by the European Medicines Agency on 7 May, follows a request by AstraZeneca. “Global demand for all COVID vaccines is now much lower and overall supply exceeds demand. This is in marked contrast to the early part of the pandemic when supply was limited and distribution very limited, especially in poorer countries.

Distribution 89

Distribution Manufacturing Medicine Pharmaceutical 89

pharmaphorum

MAY 9, 2024

A new metric developed by Phesi can predict the burden that clinical trials will impose on patients, allowing amendments that can improve the design, efficiency and cost

Patients 84

Patients 84

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

Pharmaceutical Technology

MAY 9, 2024

Anixa Biosciences has expanded its partnership with Cleveland Clinic to develop additional vaccines for cancers.

98

98

pharmaphorum

MAY 9, 2024

Google DeepMind and Isomorphic Labs' newly launched AlphaFold 3 extends the power of the AI model to 'all life’s molecules'

94

94

PharmaTimes

MAY 9, 2024

The subtype accounts for 20% of all T-cell leukaemias, a rare form of blood cancer which produces too many abnormal T-cells

Patients 88

Patients 88

European Pharmaceutical Review

MAY 9, 2024

Regulatory agencies in the US across three sectors: agriculture and environmental, have produced a joint plan to “update, streamline, and clarify” regulations and oversight mechanisms for biotechnology products. The plan, developed by the US Environmental Protection Agency (EPA), the US Food and Drug Administration (FDA), and the US Department of Agriculture (USDA), helps to address US President Biden’s related goals, including and improving the “transparency, predictability, coordination, and

Food and Drug Administration 71

Food and Drug Administration FDA Engineering Consulting 71

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

PharmaTimes

MAY 9, 2024

Anticancer drugs will be responsible for 90% of nearly 612,000 predicted US cancer deaths in 2024

Pharma 97

Pharma 97

PharmaTech

MAY 9, 2024

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.

72

72

pharmaphorum

MAY 9, 2024

NICE updates guidance on tumour profiling tests to steer adjuvant chemotherapy decisions to include lymph node-positive early breast cancer.

62

62

PharmaTech

MAY 9, 2024

Tara Dougal, content director, Pharma, Informa Markets, discusses successes and insights from this year’s CPHI North America and the agenda for the upcoming CPHI Milan.

Pharma 59

Pharma Marketing 59

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

PharmExec

MAY 9, 2024

In this Pharmaceutical Executive video interview, Panna Sharma, CEO, Lantern Pharma, talks about ensuring global access to LP-284, particularly in regions with limited resources

Pharma 52

Pharma Pharmaceutical 52

Vodori

MAY 9, 2024

Adding a new claim to your campaign requires careful handling to ensure it's not only medically sound but also fits well with your campaign's goals. This guide will walk you through seven crucial steps to evaluate, fine-tune, and smoothly integrate new claims. From gauging relevance to assessing value, confirming reliability, and crafting clear messages, each step plays a vital role in shaping the outcome and effectiveness of your campaign.

Medical 52

Medical Marketing 52

PharmExec

MAY 9, 2024

Strategic financing from Oaktree Capital Management and OMERS Life Sciences is expected to support the US launch of ensifentrine, Verona’s promising chronic obstructive pulmonary disease treatment.

Management 52

Management Pharma 52

Pharmaceutical Technology

MAY 9, 2024

Clinical trials are growing across Africa as the immense potential of the continent starts to be realised. Sponsors and CROs are tapping into the unsaturated patient pools, more diverse populations, and competitive operations costs.

Competition 52

Competition Patients 52

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization